121876-87-7

Upstream product

• 63-74-1 sulfanilamide 
• 1694-29-7 3-chloropentane-2,4-dione 

Downstream Products

• 121876-83-3 4-(4-Methyl-2-{N'-[1-phenyl-meth-(Z)-ylidene]-hydrazino}-thiazol-5-ylazo)-benzenesulfonamide 
• 121876-86-6 4-(2-{N'-[1-(4-Dimethylamino-phenyl)-meth-(Z)-ylidene]-hydrazino}-4-methyl-thiazol-5-ylazo)-benzenesulfonamide 
• 121876-85-5 4-(2-{N'-[1-(4-Hydroxy-3-methoxy-phenyl)-meth-(Z)-ylidene]-hydrazino}-4-methyl-thiazol-5-ylazo)-benzenesulfonamide 
• 1145681-93-1 2-[5-acetyl-3-(4-sulfamoyl-phenyl)-3H-[1,3,4]thiadiazol-2-ylidenehydrazinocarbonyl]-N-thiazol-2-yl-acetamide 
• 1145681-88-4 2-[5-acetyl-3-(4-sulfamoyl-phenyl)-3H-[1,3,4]thiadiazol-2-ylidene]-N-thiazol-2-yl-malonamic acid methyl ester 
• 1187067-33-9 2-[5-acetyl-3-(4-aminosulfonylphenyl)-1,3,4-thiadiazol-2(3H)-ylidene]-3-oxo-3-piperidin-1-yl propanenitrile 
• 1187067-23-7 4-methyl-2-{[2-(4-(piperidin-1-yl)benzylidene)hydrazino]}-5-[(4-aminosulfonylphenyl)azo]-1,3-thiazole 
• 1529774-38-6 4-(2-(3,6-dimethyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazin-7-ylidene)hydrazinyl)benzenesulfonamide 
• 1529774-39-7 4-(2-(6-methyl-3-phenyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazin-7-ylidene)hydrazinyl)benzenesulfonamide 
• 1529774-40-0 4-(5-acetyl-2-(cyanophenylmethylene)-1,3,4-thiadiazol-3(2H)-yl)benzenesulfonamide 
• 1529774-41-1 ethyl 2-(5-acetyl-3-(4-sulfamoylphenyl)-1,3,4-thiadiazol-2(3H)-ylidene)-2-cyanoacetate 
• 1529774-42-2 4-(5-acetyl-2-(1-cyano-2-oxo-2-phenylethylidene)-1,3,4-thiadiazol-3(2H)-yl)benzenesulfonamide 
• 1529774-43-3 2-(5-acetyl-3-(4-sulfamoylphenyl)-1,3,4-thiadiazol-2(3H)-ylidene)-2-cyano-N-(4-sulfamoylphenyl)acetamide 
• 1529774-44-4 (1Z,2E)-2-(2-benzoylhydrazono)-N′-(4-sulfamoylphenyl)propanehydrazonoyl chloride 

Relevant academic research and scientific papers

Synthesis, X-ray crystallographic analysis, DFT studies and biological evaluation of triazolopyrimidines and 2-anilinopyrimidines

Inspired by the reported antiviral activity of pyrimidines and triazolopyrimidines, two series of 2-anilinopyrimidines (5a-e) and 1-aryl-[1,2,4]triazolo[4,3-a]pyrimidines (14a-k) were designed and synthesized as potential antiviral agents. X-ray crystallographic study of compounds (14d) and (14k) confirmed the structure of the desired isomer and revealed the coplanarity of the fused [1,2,4]triazolo[4,3-a]pyrimidine rings with the aryl side group. DFT studies revealed insights into the mechanism of the micro-reversible cyclisation step using DFT [B3LYP-D3(BJ)/6–31++G(d,p)]. The pharmacokinetic properties and calculation of drug likeness scores (DLS) of (5a-e) and (14a-k) suggested good traditional drug-like properties and led to the synthesis of derivatives (14a-k) which were evaluated for their anti-viral activity with the most potent derivatives subjected to cytotoxicity screening. Compounds (14a), (14c), (14e), (14f) and (14k) showed moderate to strong antiviral activity with EC50 values 38 - 186 μM. Compound (14e) (DLS = 0.29) showed the best anti-CHIKV activity (EC50 = 38 μM) and lowest cytotoxicity (CC50 > 300 μg/ml) against breast cancer cell lines, MCF-7 and MD-AMB-231 and normal cell line EA.hy926. Simplification of [1,2,4]triazolo[4,3-a]pyrimidine ring, led to series (5a-e) (DLS = 0.03 - 0.77). Derivatives (5a-d) showed fair anti-CHIKV activity (EC50 > 200 μM), while (5e) emerged as the most active antiviral agent, however the most cytotoxic.

Synthesis of bulky-tailed sulfonamides incorporating pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-1(5H)-yl) moieties and evaluation of their carbonic anhydrases I, II, IV and IX inhibitory effects

Using celecoxib as lead, two novel series of sulfonamides incorporating the pyridotriazolopyrimidine scaffold have been synthesized and evaluated in vitro as inhibitors against four relevant human (h) carbonic anhydrases (CAs, EC 4.2.1.1), the cytosolic and ubiquitous hCA I and II as well as the transmembrane hCA IV and hCA IX. Most of the reported sulfonamides acted as efficient, low micromolar inhibitors of hCAI, II and IV, whereas they displayed higher efficacy in inhibiting the tumor-associated isoform hCA IX. Many derivates herein reported showed better hCA IX versus hCA II selectivity ratios compared to celecoxib or acetazolamide. Considering isoform IX is a validated target for the diagnosis and treatment of hypoxic tumors, discovery of selective CA IX inhibitors represents a promising step to unveil more effective anticancer therapies.